Sentynl Therapeutics, Inc.
Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences that acquires, develops, and commercializes FDA-approved therapies for rare and ultra-rare pediatric genetic diseases including Menkes, Progeria, and MoCD Type A.
- Company typePrivate
- Founded2015
- HeadquartersSolana Beach, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sentynl Therapeutics, Inc. does
Sentynl Therapeutics, Inc. is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (India), founded in 2015 and headquartered in Solana Beach, California. The company specializes in acquiring, developing, and commercializing treatments for rare and ultra-rare pediatric genetic diseases through a buy-and-commercialize model, with a current commercial portfolio of three FDA-approved therapies: ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A. Its technology foundation rests on proprietary drug formulations including subcutaneous copper replacement, farnesyltransferase inhibition, and cPMP substrate therapy, each targeting fatal genetic conditions that previously had no approved treatment options.
The business model centers on pharmaceutical product sales through specialty pharmacy distribution channels in the United States, supplemented by outbound royalty obligations on licensed products (e.g., tiered royalties to Cyprium Therapeutics on ZYCUBO net sales plus up to $128-129 million in aggregate sales milestones). Sentynl monetizes its portfolio through a sales-led enterprise field model employing Rare Disease Key Account Managers, Medical Science Liaisons, and an inside Key Account Consultant team that engages healthcare professionals at treatment centers of excellence. The Sentynl Cares patient support program facilitates insurance navigation and affordability assistance, while a Managed Access Program (now operated by Amsterdam-based myTomorrows) extends reach for international patients. Revenue figures are not publicly disclosed, though analyst projections estimate ZYCUBO peak sales of approximately $50 million and company-wide profitability by FY28. With 11-50 employees, the firm operates a focused ultra-rare disease specialty model targeting indications with no approved competitors.
Sentynl Therapeutics, Inc. firmographics
Firmographics- Name
- Sentynl Therapeutics, Inc.
- Legal name
- Sentynl Therapeutics, Inc.
- Website
- https://sentynl.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences that acquires, develops, and commercializes FDA-approved therapies for rare and ultra-rare pediatric genetic diseases including Menkes, Progeria, and MoCD Type A.
- Ownership category
- akta.pro rank
Sentynl Therapeutics, Inc. industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
- akta.pro secondary industry
- Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Sentynl Therapeutics, Inc. is headquartered
LocationHeadquarters
- HQ city
- Solana Beach
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Sentynl Therapeutics, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Revenue from sales of FDA-approved rare disease therapies including ZYCUBO for Menkes disease, Zokinvy for Progeria, and NULIBRY for MoCD Type A. Products distributed through specialty pharmacy channels with patient support programs.
- Royalty Revenue: Sentynl pays royalties to Cyprium Therapeutics on ZYCUBO net sales (tiered royalties) plus up to $128-129 million in aggregate sales milestones, per 2023 agreement. Also likely pays royalties on other licensed products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Patient assistance program for US residents |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels6 records
Sentynl Therapeutics, Inc. product offering
Product offeringCore offering
Sentynl Therapeutics is a U.S.-based commercial-stage biopharmaceutical company that develops, in-licenses, and commercializes FDA-approved drug therapies for ultra-rare pediatric genetic diseases. Its marketed portfolio comprises ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A, distributed through specialty pharmacy channels and supported by the Sentynl Cares patient access program.
Product overview
Sentynl Therapeutics is a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences, focused on acquiring, developing, and commercializing treatments for rare and ultra-rare diseases. The company's commercial portfolio includes three FDA-approved products: ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A. Additionally, Sentynl is advancing Progerinin through Phase 2A trials for Progeria. The company operates exclusively in the United States and supports patients through the Sentynl Cares patient access program.
Differentiator
Problem solved
Functional benefit
Brands
- Sentynl Cares: Patient access and support program offering assistance with insurance coverage, affordability issues, and treatment education for patients prescribed Sentynl therapies.
Products and services
- ZYCUBO (copper histidinate) FDA-approved copper replacement therapy for the treatment of Menkes disease in pediatric patients. Administered subcutaneously as a lyophilized powder reconstituted for injection, it is the first and only approved treatment for this rare, fatal genetic disorder affecting copper absorption and transport, demonstrating 78–80% reduction in mortality risk in early-treated patients.
- Zokinvy (lonafarnib) FDA-approved oral farnesyltransferase inhibitor treatment for Hutchinson-Gilford Progeria Syndrome and processing-deficient progeroid laminopathies. It is the only FDA-approved treatment for progeria, a fatal genetic disorder causing premature aging in children, with approvals in the US (2020), EU (2022), Great Britain (2022), and Japan (2024).
- NULIBRY (fosdenopterin) Approved substrate replacement therapy for molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly in infants with a median overall survival age of about four years. Approved in the US (2021), EU (2022), Israel (2022), and Great Britain (2024).
- Progerinin (SLC-D011) Investigational drug candidate for Hutchinson-Gilford Progeria Syndrome currently in Phase 2A clinical trials. Licensed from PRG S&T, with Sentynl gaining full rights upon milestone completion, advancing the company's pipeline in rare aging diseases.
- Sentynl Cares Patient access and support program providing insurance navigation, affordability assistance, treatment follow-up, and educational resources for US residents prescribed Sentynl rare disease therapies, helping patients access approved treatments such as ZYCUBO, Zokinvy, and NULIBRY.
Quantifiable outcome
- 78-80% reduction in risk of death for early-treated Menkes disease patients (median survival 177.1 months vs 17.6 months untreated)
- +2 more outcomes
Companies that use Sentynl Therapeutics, Inc.
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Sentynl Therapeutics, Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Sentynl Therapeutics, Inc. partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- PRG S&TcoreSentynl entered agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational drug for Hutchinson-Gilford Progeria Syndrome currently in Phase 2A trials. Deal allows Sentynl to begin clinical development with full rights potentially acquired upon milestone completion, aiming to develop therapies for rare aging diseases.
- Cyprium Therapeutics (Fortress Biotech)coreSentynl acquired CUTX-101 (ZYCUBO) development and commercialization rights from Cyprium in December 2023. Cyprium retains tiered royalties on net sales and up to $128-129 million in sales milestones. Sentynl purchased PRV for $205 million in February 2026. Joint Steering Committee oversees continued development.
- myTomorrowscoreSentynl transitioned its Managed Access Program (MAP) to myTomorrows, a global healthtech company based in Amsterdam. The partnership aims to expand the program's reach and improve access to treatments for ultra-rare conditions like Hutchinson-Gilford Progeria Syndrome, with potential extension to other access programs.
- Eiger BioPharmaceuticalscoreSentynl acquired global proprietary rights to Zokinvy (lonafarnib) from Eiger BioPharmaceuticals in May 2024 following court-approved sale amid Eiger's bankruptcy proceedings. Zokinvy is approved in US (2020), EU, Great Britain (2022), and Japan (2024) for progeria treatment.
- Rady Children's Institute for Genomic MedicineminorSentynl is a founding member of BeginNGS program supporting newborn screening for 419 treatable genetic disorders. Phase 2 support to identify treatable genetic diseases in newborns through genomic sequencing.
- BridgeBio PharmacoreAsset purchase agreement for NULIBRY (fosdenopterin) for treatment of MoCD Type A. NULIBRY is first and only approved therapy in US, EU, Israel, and Great Britain for this ultra-rare, life-threatening genetic disorder.
- Menkes FoundationminorSentynl joins the global Menkes disease community including the Menkes Foundation in recognizing Menkes Disease Awareness Month. Collaboration on disease awareness and patient support.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Sentynl Therapeutics, Inc. competitors and assessment
Company assessmentBroad incumbents
- Recordati Rare Diseases: Pharmaceutical group with dedicated rare disease division offering treatments for rare conditions globally. Comparable in rare disease commercialization but operates within broader specialty pharma portfolio.
- Alexion Pharmaceuticals (AstraZeneca Rare Disease): Pioneer in rare disease biopharmaceuticals, now part of AstraZeneca. Comparable ultra-rare disease focus with established global infrastructure but operates at significantly larger scale as part of a major pharma.
Emerging players
- Alnylam Pharmaceuticals: Commercial-stage biopharmaceutical company developing RNA interference therapeutics for rare genetic diseases. Comparable focus on rare diseases with novel therapeutic modalities and similar ultra-rare disease commercial dynamics.
- Ionis Pharmaceuticals: Biopharmaceutical company developing antisense oligonucleotide therapies for serious and rare diseases. Comparable in targeting rare genetic conditions with novel therapeutic platforms and similar patient population scale.
Direct peers
- Amicus Therapeutics: Biopharmaceutical company developing treatments for rare metabolic diseases including lysosomal storage disorders. Comparable focus on genetic rare diseases with high unmet need and similar commercial scale.
- BridgeBio Pharma: Genetic disease-focused biopharmaceutical company that developed NULIBRY before selling it to Sentynl. Direct comparable in ultra-rare genetic disease therapeutic development and commercialization strategy.
- Sarepta Therapeutics: Focused on rare neuromuscular diseases with multiple approved genetic medicines. Comparable strategy of acquiring/developing orphan drugs for small patient populations with high pricing power.
- Ultragenyx Pharmaceutical: Commercial-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases with multiple FDA-approved products. Highly comparable business model of developing and commercializing therapies for small patient populations with high unmet need.
- BioMarin Pharmaceutical: Global biopharmaceutical company specializing in rare genetic diseases with multiple approved therapies. Comparable focus on ultra-rare pediatric disorders and similar commercial model targeting specialty physicians and treatment centers.
- Swedish Orphan Biovitrum (Sobi): Specialty biopharmaceutical company focused on rare diseases with established European and US operations. Comparable orphan drug commercialization model targeting ultra-rare patient populations across multiple geographies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Sentynl Therapeutics, Inc. social profiles
Digital presenceSentynl Therapeutics, Inc. compliance and trust
Trust signalCompliance1 record
Sentynl Therapeutics, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sentynl Therapeutics, Inc. leadership team
Management profileNumber of profiles
Profiles5 records
Sentynl Therapeutics, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sentynl Therapeutics, Inc. M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sentynl Therapeutics, Inc.
What does Sentynl Therapeutics, Inc. do?
Sentynl Therapeutics is a U.S.-based commercial-stage biopharmaceutical company that develops, in-licenses, and commercializes FDA-approved drug therapies for ultra-rare pediatric genetic diseases. Its marketed portfolio comprises ZYCUBO (copper histidinate) for Menkes disease, Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency Type A, distributed through specialty pharmacy channels and supported by the Sentynl Cares patient access program.
Is Sentynl Therapeutics, Inc. a public or private company?
Sentynl Therapeutics, Inc. is a private company. It is classified as corporate owned and is currently operating.
When was Sentynl Therapeutics, Inc. founded?
Sentynl Therapeutics, Inc. was founded in 2015. It employs 11 to 50 people.
Where is Sentynl Therapeutics, Inc. based?
Sentynl Therapeutics, Inc. is headquartered in Solana Beach, United States, in the North America region.
How does Sentynl Therapeutics, Inc. make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are royalty Revenue.
Who are Sentynl Therapeutics, Inc.'s main competitors?
Broad incumbents on record are Recordati Rare Diseases and Alexion Pharmaceuticals (AstraZeneca Rare Disease). Emerging players are Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Direct peers are Amicus Therapeutics, BridgeBio Pharma, Sarepta Therapeutics, Ultragenyx Pharmaceutical, BioMarin Pharmaceutical and Swedish Orphan Biovitrum (Sobi).
Does Sentynl Therapeutics, Inc. have an API?
No public API is recorded for Sentynl Therapeutics, Inc..
What industry is Sentynl Therapeutics, Inc. in?
Sentynl Therapeutics, Inc.'s product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of CRAOAHAD, Specialty Pharmacy & Biologics Distribution. Its NAICS code is 54171 and its SIC code is 2836.